1. Breast Cancer Drug Avastin Faces FDA Panel
... under, allowed for the appeal. Despite the ongoing battle, many doctors are already opting not to prescribe Avastin, according to Charlotte Arnold, a Genentech spokeswoman. Only 20-25 percent of new breast cancer patients receive the drug, down from the former 60 percent before the panel voted (Hellerman). The accelerated approval program began in 1992 so patients waiting for new, promising ... treatments could receive medicine earlier. Four cancer therapy drugs, all approved under the accelerated system, have been withdrawn by the companies who make them. These drugs include Ethyol use...
- Word Count: 1317
- Approx Pages: 5
- Has Bibliography
- Grade Level: Undergraduate